Zobrazeno 1 - 10 of 28 pro vyhledávání: '"Hebron ML"'
2
Akademický článek
c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer's disease.
Autor: Stevenson M; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington DC, USA., Hebron ML; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington DC, USA., Liu X; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington DC, USA., Balaraman K; Medicinal Chemistry Shared Resource, Department of Chemistry, Georgetown University Medical Center, Washington DC, USA., Wolf C; Medicinal Chemistry Shared Resource, Department of Chemistry, Georgetown University Medical Center, Washington DC, USA., Moussa C; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington DC, USA cem46@georgetown.edu.
Publikováno v: Life science alliance [Life Sci Alliance] 2024 Jul 15; Vol. 7 (10). Date of Electronic Publication: 2024 Jul 15 (Print Publication: 2024).
Zobrazit plný text záznamu
3
Akademický článek
Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer's disease.
Autor: Stevenson M; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC, 20057, USA., Varghese R; Genomics and Epigenomics Shared Resource, Department of Oncology, Georgetown University Medical Center, Building D, 4000 Reservoir Rd, NW, Washington, DC, 20057, USA., Hebron ML; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC, 20057, USA., Liu X; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC, 20057, USA., Ratliff N; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC, 20057, USA., Smith A; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC, 20057, USA., Turner RS; Memory Disorders Program, Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Rd, NW, Washington, DC, 20057, USA., Moussa C; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC, 20057, USA. cem46@georgetown.edu.
Publikováno v: Journal of neuroinflammation [J Neuroinflammation] 2023 May 16; Vol. 20 (1), pp. 116. Date of Electronic Publication: 2023 May 16.
Zobrazit plný text záznamu
4
Correction: Parkin ubiquitinates TAR-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6).
Autor: Hebron ML, Lonskaya I, Sharpe K, Weerasinghe PPK, Algarzae NK, Shekoyan AR, Moussa CE
Publikováno v: The Journal of biological chemistry [J Biol Chem] 2023 Jan; Vol. 299 (1), pp. 102828. Date of Electronic Publication: 2022 Dec 29.
Zobrazit plný text záznamu
5
Akademický článek
Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington's Disease Patients.
Autor: Anderson KE; MedStar Georgetown University Hospital Huntington's Disease Research, Education and Care Center, Department of Psychiatry and Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., Stevenson M; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., Varghese R; Genomics and Epigenomics Shared Resource, Department of Oncology, Georgetown University Medical Center, Building D, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., Hebron ML; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., Koppel E; MedStar Georgetown University Hospital Huntington's Disease Research, Education and Care Center, Department of Psychiatry and Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., McCartin M; MedStar Georgetown University Hospital Huntington's Disease Research, Education and Care Center, Department of Psychiatry and Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., Kuprewicz R; MedStar Georgetown University Hospital Huntington's Disease Research, Education and Care Center, Department of Psychiatry and Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., Matar S; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., Ferrante D; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC 20057, USA., Moussa C; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Building D, Room 265, 4000 Reservoir Rd, NW, Washington, DC 20057, USA.
Publikováno v: Metabolites [Metabolites] 2022 Dec 06; Vol. 12 (12). Date of Electronic Publication: 2022 Dec 06.
Zobrazit plný text záznamu
6
Akademický článek
Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies.
Autor: Pagan FL; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Lewy Body Dementia Association Research Center of Excellence Georgetown University Medical Center Washington DC USA.; MedStar Georgetown University Hospital Movement Disorders Clinic Department of Neurology Washington DC USA., Torres-Yaghi Y; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Lewy Body Dementia Association Research Center of Excellence Georgetown University Medical Center Washington DC USA.; MedStar Georgetown University Hospital Movement Disorders Clinic Department of Neurology Washington DC USA., Hebron ML; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Lewy Body Dementia Association Research Center of Excellence Georgetown University Medical Center Washington DC USA., Wilmarth B; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Lewy Body Dementia Association Research Center of Excellence Georgetown University Medical Center Washington DC USA.; MedStar Georgetown University Hospital Movement Disorders Clinic Department of Neurology Washington DC USA., Turner RS; Memory Disorders Program Department of Neurology Georgetown University Medical Center Washington DC USA., Matar S; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Lewy Body Dementia Association Research Center of Excellence Georgetown University Medical Center Washington DC USA., Ferrante D; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Lewy Body Dementia Association Research Center of Excellence Georgetown University Medical Center Washington DC USA., Ahn J; Department of Biostatistics Bioinformatics and Biomathematics Georgetown University Medical Center Washington DC USA., Moussa C; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Lewy Body Dementia Association Research Center of Excellence Georgetown University Medical Center Washington DC USA.
Publikováno v: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2022 Jun 01; Vol. 8 (1), pp. e12296. Date of Electronic Publication: 2022 Jun 01 (Print Publication: 2022).
Zobrazit plný text záznamu
7
Akademický článek
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
Autor: Pagan FL; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, District of Columbia, USA., Wilmarth B; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, District of Columbia, USA., Torres-Yaghi Y; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, District of Columbia, USA., Hebron ML; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA., Mulki S; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA., Ferrante D; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA., Matar S; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA., Ahn J; Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, District of Columbia, USA., Moussa C; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA.
Publikováno v: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2021 Mar; Vol. 36 (3), pp. 740-749. Date of Electronic Publication: 2020 Nov 20.
Zobrazit plný text záznamu
8
Akademický článek
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
Autor: Turner RS; Memory Disorders Program, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA., Hebron ML; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA., Lawler A; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA., Mundel EE; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA., Yusuf N; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA., Starr JN; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA., Anjum M; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA., Pagan F; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA., Torres-Yaghi Y; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA., Shi W; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA., Mulki S; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA., Ferrante D; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA., Matar S; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA., Liu X; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA., Esposito G; Division of Nuclear Medicine, Washington, DC, USA., Berkowitz F; Department of Radiology, MedStar Georgetown Hospital, Washington, DC, USA., Jiang X; Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA., Ahn J; Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, DC, USA., Moussa C; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.
Publikováno v: Annals of neurology [Ann Neurol] 2020 Jul; Vol. 88 (1), pp. 183-194. Date of Electronic Publication: 2020 May 28.
Zobrazit plný text záznamu
9
Akademický článek
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
Autor: Pagan FL; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Hebron ML; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC., Wilmarth B; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Torres-Yaghi Y; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Lawler A; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Mundel EE; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Yusuf N; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Starr NJ; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Anjum M; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Arellano J; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Howard HH; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC., Shi W; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC., Mulki S; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC., Kurd-Misto T; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC., Matar S; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC., Liu X; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC., Ahn J; Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, DC., Moussa C; Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC.; Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC.
Publikováno v: JAMA neurology [JAMA Neurol] 2020 Mar 01; Vol. 77 (3), pp. 309-317.
Zobrazit plný text záznamu
10
Akademický článek
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Autor: Pagan FL; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia.; Movement Disorders Clinic Department of Neurology MedStar Georgetown University Hospital Washington District of Columbia., Hebron ML; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia., Wilmarth B; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia.; Movement Disorders Clinic Department of Neurology MedStar Georgetown University Hospital Washington District of Columbia., Torres-Yaghi Y; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia.; Movement Disorders Clinic Department of Neurology MedStar Georgetown University Hospital Washington District of Columbia., Lawler A; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia., Mundel EE; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia.; Movement Disorders Clinic Department of Neurology MedStar Georgetown University Hospital Washington District of Columbia., Yusuf N; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia.; Movement Disorders Clinic Department of Neurology MedStar Georgetown University Hospital Washington District of Columbia., Starr NJ; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia.; Movement Disorders Clinic Department of Neurology MedStar Georgetown University Hospital Washington District of Columbia., Arellano J; Movement Disorders Clinic Department of Neurology MedStar Georgetown University Hospital Washington District of Columbia., Howard HH; Movement Disorders Clinic Department of Neurology MedStar Georgetown University Hospital Washington District of Columbia., Peyton M; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia., Matar S; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia., Liu X; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia., Fowler AJ; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia., Schwartz SL; Department of Pharmacology Georgetown University Medical Center Washington District of Columbia., Ahn J; Department of Biostatistics, Bioinformatics and Biomathematics Georgetown University Medical Center Washington District of Columbia., Moussa C; Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia.
Publikováno v: Pharmacology research & perspectives [Pharmacol Res Perspect] 2019 Mar 12; Vol. 7 (2), pp. e00470. Date of Electronic Publication: 2019 Mar 12 (Print Publication: 2019).
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje